Minpu Zhang1
Cun Liu
Ye Li
Huayao Li
Jingyang Liu
Changgang Sun- 1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
- 2College of Traditional Chinese Medicine, Weifang Medical University, Weifang, China
- 3Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China
- 4Department of Thyroid and Breast Surgery, Weifang People’s Hospital, Weifang, China
- 5Department of Oncology, Weifang Traditional Chinese Hospital, Weifang, China
Galectin-9 (Gal-9) is a vital member of the galectin family, functioning as a multi-subtype galactose lectin with diverse biological roles. Recent research has revealed that Gal-9’s interaction with tumors is an independent factor that influences tumor progression. Furthermore, Gal-9 in the immune microenvironment cross-talks with tumor-associated immune cells, informing the clarification of Gal-9’s identity as an immune checkpoint. A thorough investigation into Gal-9’s role in various cancer types and its interaction with the immune microenvironment could yield novel strategies for subsequent targeted immunotherapy. This review focuses on the latest advances in understanding the direct and indirect cross-talk between Gal-9 and hematologic malignancies, in addition to solid tumors. In addition, we discuss the prospects of Gal-9 in tumor immunotherapy, including its cross-talk with the ligand TIM-3 and its potential in immune-combination therapy.
1 Introduction
Galectins (Gals) are a family of lectins defined by a shared amino acid sequence. Their structure features a carbohydrate recognition domain (CRD) that specifically binds to polysaccharides containing ß-galactoside. This structural feature serves as a foundation for understanding the function of such sugar chain-binding proteins (Nagae et al., 2008). Apart from recognizing the typical glycan structure, each member of the Gals family exhibits preferential binding to specific glycosylated proteins and/or lipids found on the cell surface or in the extracellular matrix (Barondes et al., 1994a; Barondes et al., 1994b). This specific binding influences the interaction between Gals and human cells. There are 16 identified Gals that exert both intracellular and extracellular effects. They are involved in various biological functions, including the regulation of cell growth, apoptosis, pre-mRNA splicing, cell-cell and cell-matrix adhesion, cell polarity, and innate/acquired immunity. These functions may be linked to the relationship between Gals and glycated proteins and/or lipids (The figure is depicted in Figure 1) (Chou et al., 2018). The widespread distribution of Gals in most organs of the body likely contributes to their broad range of biological functions and their ability to interact with various target cells.
FIGURE 1. Structure and structural domains of Gal-9 and their biological functions associated with different receptors. Gal-9 has been found in three natural Gal-9 isoforms with different interdomain linker lengths (long, medium and short). In addition, a recombinant form of Gal-9 with a linker length of two amino acids has been produced. In addition, the receptors for Gal-9 are complex and diverse: lysosomal-associated membrane protein 2 (LAMP2), TNF receptor superfamily member CD137, CD44 adhesion molecule, CD40, macrophage marker CD206, protein disulfide bond isomerase (PDI) involved in T cell migration, immune receptors PD-1, TIM-3 and VISTA, Dectin-1, which are clinically relevant, in addition to bacterial lipopolysaccharide (LPS), 4-1BB, which is associated with inflammatory responses.
Recent articles have shed light on the involvement of Gals in tumors, where alterations in their expression levels are closely linked to tumor biology. Aberrant expression of Gals has been implicated in tumorigenesis, progression, and metastasis, making several members of the family potential prognostic markers for various types of cancer (Kapetanakis and Busson, 2023). Galectin-9 (Gal-9), as a member of the Gals family, is a soluble molecule with broad availability and noteworthy significance due to its diverse biological functions and potent immunomodulatory effects. Gal-9 was first discovered as an effective eosinophil chemoattractant and is widely distributed in liver, small intestine, thymus, lung, spleen, kidney and other organs (Wada and Kanwar, 1997). In addition, research by Hirashima M et al. found that Gal-9 cannot be detected in endothelial cells, fibroblasts and astrocytes under physiological conditions, but some cytokines (such as IFN-γ or IL-1β) can be upregulated (Hirashima et al., 2002). The expression of Gal-9 indicates that the general biological function and regulatory mechanism of Gal-9 are different from those under pathological conditions. The characteristic regulation of alternative splicing in Gal-9 gives rise to a wide range of biological functions in different cell types, playing a pivotal role in shaping cellular phenotypes and physiological processes (Marasco and Kornblihtt, 2023). For example, in endothelial cell biology, isoforms of Gal-9 can influence the activation of resting endothelial cells and the migration of activated endothelial cells. While distinct effects can be observed in vitro, this study shows that all isoforms of Gal-9 can hinder angiogenesis in vivo (Aanhane et al., 2018). Since alternative splicing occurs, Gal-9 manifests in three isoforms with varying lengths of linking peptides, and different cell types can express one, two, or all three isoforms (Yasinska et al., 2019). Notably, Gal-9 exhibits unique activity profiles, acting as a “double-edged sword” depending on the cellular localization of its binding partners. Intracellular Gal-9, for example, stimulates the expression of pro-inflammatory cytokines in monocytes by binding to the transcription factor NF-IL6, while extracellular Gal-9 triggers monocyte death.
The diverse range of biological functions exhibited by Gal-9 has resulted in various impacts on tumors (Chou et al., 2018). In certain types of cancers, such as breast cancer (Yasinska et al., 2019), nasopharyngeal carcinoma (Chen et al., 2017), and melanoma (Kageshita et al., 2002), high expression of Gal-9 has been associated with cancer cell aggregation, while low expression is linked to cell invasion. In cases of carcinoma in situ, Gal-9’s high expression facilitates communication between cells and the extracellular matrix, whereas low expression in metastatic tumors suggests a potential inhibitory role in tumor metastasis. For example, in breast cancer, previous reports have suggested that Gal-9 exhibits anti-metastatic properties (Irie et al., 2005; Yamauchi et al., 2006). Furthermore, Gal-9 demonstrates anti-proliferative abilities in malignant tumors, particularly in gastrointestinal malignancies. The acquisition of sustained proliferative signaling is one of the hallmark features of cancer, as recognized by cancer researchers (Hanahan and Weinberg, 2000). Therefore, the ability to inhibit tumor cell proliferation holds substantial importance in tumor therapy. However, it is important to note that other features are also crucial in the context of tumors. Gal-9 possesses multiple properties within the tumor immune microenvironment (TIME) and can be expressed to varying extents in nearly all immune cells (Chaudhary et al., 2022), including tumor-associated macrophages (TAM) (Qi et al., 2019), antigen-presenting cells (APCs) (Ashraf et al., 2017), Regulatory T-cells (Treg cells) (Ashraf et al., 2015), and T-cells.
Gal-9 plays a crucial role in tumor pathogenesis, and further research exploring its regulation in tumors can enhance our understanding of its mechanisms. Promising therapeutic activity against malignancies has been observed in relevant in vivo and in vitro experiments, as well as in preclinical models involving Gal-9. This review aimed to provide a comprehensive overview of changes in Gal-9 expression in hematologic malignancies and solid tumors, shedding light on their significance in these contexts. Furthermore, it delves into the intricate nature of Gal-9 as a multilateral partner in the TIME. It systematically elucidates Gal’s role in the TIME, establishing its status within this complex ecosystem. Moreover, this review proposes that targeting Gal-9 in combination with immunotherapy could present a new avenue for tumor treatment in the “post-immune era”, offering renewed hope in the field.
2 Overview of the structure and general biological functions of Galectin-9
Gal-9 belongs to the “tandem-repeat type” galectin family, which was originally recognized as a potent eosinophil chemotactic agent, and consists of an N-terminal Carbohydrate Recognition Domain (N-CRD) and a C-terminal CRD (C-CRD), each comprising 148 and 149 amino acids, respectively (Wiersma et al., 2013). The presence of the CRD is a defining structural hallmark shared by all members of the galectin family. Extensive studies by Nagae M et al. have explored the structural features of Gal-9, revealing that the overall structure of both the N-CRD and C-CRD is similar. The differences primarily arise from the insertion or deletion of amino acid residues, leading to specificity in carbohydrate binding (Nagae et al., 2006). The presence of N- and C-CRDs contributes to the biological effects of Gal-9, and studies have shown that N-CRDs activate dendritic cells more efficiently, whereas C-CRDs are major determinants of receptor recognition and death pathway signaling in T-cells (Wiersma et al., 2013).
Human Gal-9 has three natural isoforms: Gal-9 (S), Gal-9 (M), and Gal-9 (L), which differ in the length of the linker region separating the N-CRD and C-CRD. As mentioned earlier, alternative splicing of Gal-9 results in the selective expression of these isoforms in different cell types. For instance, T cells selectively overexpress Gal-9(M) and Gal-9(L) (Sato et al., 2002). In a review by Wiersma VR et al. (Wiersma et al., 2013), it was noted that the difference between Gal-9 isoforms is associated with the linkers and primarily affects the ability of the isoforms to bind to glucose ligands. However, this difference does not impact the function of Gal-9 in attracting eosinophils and inducing T cell apoptosis. Consequently, future investigations exploring the relationship between Gal-9 and tumor immune cells, as well as the development of immune drugs targeting Gal-9, may be less constrained by the isoform variations. Available data suggest that Gal-9 has a wide range of biological functions in normal cell biology and pathology. Under hyperimmune conditions, Gal-9 can act as a negative regulator of the immune system, while under immune compromised conditions, it can act as an immune enhancer. This role as a regulator of immune homeostasis makes it not surprising that Gal-9 its a candidate for the treatment of a wide range of diseases and gives it a place in the complex tumor immune microenvironment.
3 Role of Gal-9 in malignancy
Gal-9 plays a role in various types of hematologic malignancies and solid tumors, as demonstrated in related cell-based studies and animal and clinical experiments (The data are shown in Table 1). In addition, common mechanisms of Gal-9 in multiple cell types and tumors were explored by us (Figure 2).
TABLE 1. Role of Gal-9 in various cancers.
FIGURE 2. Multifunctions and meachanism of Gal-9 on various cells and tumors.
3.1 Hematologic malignancy
3.1.1 Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
A study conducted by Kikushige Y et al. (Kikushige et al., 2015) in 2015 reported that human AML cells can secrete large amounts of Gal-9 into the bloodstream. Gal-9 expression is upregulated in patients with AML who had an unsuccessful chemotherapy (Dama et al., 2019). The study showed that Gal-9 in AML cells can bind to its receptor T cell immunoglobulin and mucin-domain containing-3 (TIM-3), which is expressed on the surface of AML stem cells. Reports also suggest that the interaction between Gal-9 and TIM-3 supports the maintenance of leukemia-initiating cells and promotes immune eversion in AML models (Goncalves Silva et al., 2017; Ruvolo, 2019; Gallazzi et al., 2022). Yasinska IM et al. (Yasinska et al., 2020) reported that Gal-9 produced by AML cells can induce a pro-apoptotic process in T cells expressing V-domain Ig-containing suppressors of T cell activation (VISTA). However, Gal-9 does not promote apoptosis in natural killer cells (NK cells) that do not express VISTA. The VISTA protein expressed by T cells recognizes Gal-9 secreted by AML cells and acts as its ligand. Simultaneously, soluble VISTA released by AML cells enhances the action of Gal-9, leading to the formation of a multiprotein complex on the surface of T cells. This complex acts as a molecular barrier, ultimately activating granzyme B in cytotoxic T cells and triggering apoptosis. Clinical data suggests that patients with AML exhibit elevated levels of plasma Gal-9, and the levels are associated with a poor prognosis for the disease (Asayama et al., 2017). Additionally, approximately 10%–40% of patients with MDS progress to AML. Studies have demonstrated significantly higher levels of plasma Gal-9 in patients with MDS and those progressing from MDS to the AML stage compared to normal individuals.
3.1.2 Chronic lymphocytic leukemia (CLL)
Previous studies have demonstrated that Gal-9 expression is elevated in peripheral blood cells of patients with CLL, particularly in those with advanced stages of the disease (Taghiloo et al., 2017). This indicates a potential association between Gal-9 expression and disease progression in CLL. Pang et al. (2021) further confirmed the elevation of Gal-9/TIM-3 in CLL and its correlation with disease progression. Serum levels of Gal-9 and IL-10 are elevated in patients with CLL, particularly in patients in Binet stages B and C, whereas the levels of interferon-γ (IFN-γ) are decreased. Based on these findings, Zheng et al. (2019) raised the possibility that elevated Gal-9 levels in CLL may contribute to immune dysfunction characterized by the aggregation of non-functional and exhausted CD8+ T cells. The immune system plays a critical role in inhibiting tumor cell proliferation (Gajewski et al., 2013), and the impairment of the immune system mediated by Gal-9 may potentially promote the proliferation of leukemia cells in CLL.
3.1.3 B-cell acute lymphoblastic leukemia (B-ALL)
Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the abnormal proliferation of B- or T-lineage cells in the bone marrow. CAR-T cell therapy has been used for the treatment of acute B-lymphocytic leukemia (BLL) for over a decade, showing clinical benefit. However, the emergence of additional data has identified patient-specific risk factors associated with this therapy. The influence of obesity factors in B-ALL has been investigated, and a study revealed that adipocyte secretomes can upregulate the expression of Gal-9 on the surface of human acute B-ALL cells, leading to an increased chemoresistance (Lee et al., 2022). The study also demonstrated that the upregulation of Gal-9 on B-ALL cells mediated by adipocytes could potentially overcome obesity-induced chemoresistance through antibody-based therapy.
Gal-9 signaling in AML cells activates the AKT and ERK signaling pathways. Interestingly, exposure of B-ALL cells to factors secreted by adipocytes also leads to activation of these signaling pathways. This suggests a potential shared mechanism involving Gal-9 in different leukemia subtypes. Studies are currently underway to explore the early integration of immunotherapeutic agents such as inotuzumab and blinatumomab with low-dose chemotherapy (dose-dense mini-Hyper-CVD-inotuzumab-blinatumomab) in the frontline setting for the treatment of B-ALL (Jabbour et al., 2023). Following this approach, CAR T-cell consolidation at high doses without maintenance therapy is being proposed for at-risk patients Inhibition of Gal-9 represents an unexplored approach that could potentially improve the prognosis of patients with B-ALL and other leukemia subtypes, particularly in the presence of obesity-related factors.
3.2 Solid malignancies
3.2.1 Malignant melanoma
The existing data suggest that Gal-9 plays a tumor-suppressive role in malignant melanoma (Wiersma et al., 2012). Studies have shown that the absence of Gal-9 is strongly associated with metastatic progression and that recombinant Gal-9 has hitherto unrecognized cytotoxic effects on human melanoma cells. Previous studies have reported that Gal-9 expression is high in nevi and primary melanoma lesions but low in metastatic melanoma lesions (Kageshita et al., 2002). Ectopic expression of Gal-9 inhibits metastasis in Gal-9-deficient B16F10 mouse melanoma cells (Nobumoto et al., 2008). And Gal-9, through its interaction with CD206 on M2 macrophages, promotes angiogenesis, chemokine production, and tumor growth, with corresponding poor patient prognosis (Enninga et al., 2018). However, several recent studies have shown that Gal-9 can be involved in melanoma metastasis under specific conditions, and CCR7 is highly expressed in metastases from melanoma patients, where a subpopulation of CCR7+ melanoma cells was found to co-express PD-L1 and Gal-9 (Cristiani et al., 2019). A study by Melief SM et al. identified the presence of Gal-9+ dendritic cells/dendritic cell-like macrophages to be associated with better survival in patients with stage IV melanoma (Melief et al., 2017).
In addition, with the advent of targeted therapies and checkpoint inhibitors, adoptive cell transfer has become an important salvage therapy for patients with stage IV melanoma. The emergence of Gal-9+ dendritic cells/dendritic cell-like macrophages is most commonly seen in patients with sustained clinical benefit following adoptive cell transfer therapy. Epigenetic regulation of TIM-3 and Gal-9 in malignant melanoma has been innovatively explored by Holderried et al. (2019), specifically through DNA methylation. Although studies on Gal-9 in melanoma are scattered and it is not yet possible to summarize the common mechanisms, the above studies provide insights into Gal-9 as a predictive bioinformatic marker in the future.
3.2.2 Colon cancer
Exogenous rLGALS9, a lysosome inhibitor, exhibits high cytotoxicity against KRAS-mutated colorectal cancer cells (Wiersma et al., 2015). Exogenous rLGALS9 can undergo rapid internalization through clathrin- and protein kinase C-, RAF1-, and MAP2K1-dependent endocytosis, resulting in the accumulation of rLGALS9 in lysosomes. This process triggers cell death in colorectal cancer cells harboring refractory KRAS gene mutations. Blair et al. (2021) conducted an ELISA-based comparison of galactose lectin concentrations across different stages of multiple cancer types and found a statistically significant increase in Gal-9 levels in colon cancer. The impact of Gal-9 on human colorectal cancer cells has been directly demonstrated in studies by Morishita et al. (2021) and Sasidharan Nair et al. (2018) They showed that Gal-9 can inhibit cell proliferation through apoptosis in both in vivo and in vitro experiments. Sasidharan Nair et al. (2018) focused on exploring the influence of the Gal-9 promoter on colorectal cancer through epigenetic modifications such as DNA methylation. Notably, a meta-analysis showed that high expression of Gal-9 had a positive impact on overall survival (OS) in patients with colorectal cancer (Zhou et al., 2018). High Gal-9 expression was associated with improved OS, but did not correlate with disease-free survival (DFS) or recurrence-free survival (RFS) in solid tumors. In conclusion, the positive impact of high Gal-9 expression in colon cancer is a consensus topic in both clinical and in vitro experimental studies.
3.2.3 Breast cancer
Gal-9 on the surface of breast cancer cells acts as a protective agent against cytotoxic T-cell-induced cell death. A series of studies by Yamauchi A et al. found that Gal-9 appears to protect Gal-9-expressing tumors from immune attack, and this protective effect does stop breast cancer from metastasizing (Irie et al., 2005; Yamauchi et al., 2006; Gleason et al., 2012). Pally et al. (2022) demonstrated the high expression of Gal-9 in breast cancer epithelial cells through in vitro cell experiments, clinical samples, and analysis of publicly available database samples. The authors also revealed that high Gal-9 expression enhances the invasiveness of breast cancer cells in the early stages of invasion. Contrary to the findings of previous studies, there was a positive correlation between Gal-9 levels and the invasive potential of cancer cells, suggesting a potential role for Gal-9 in inducing breast cancer cell invasion, and posing a challenge for the potential development of Gal-9-targeted inhibitors in breast cancer. With the development of spatial biology and spatial histology, the paradox of Gal-9 in breast cancer may be resolved in the future, and spatial variability among single cells may answer why there is variability in Gal-9 findings in breast cancer. Despite the uncertainties regarding the role of Gal-9, the presence of both Gal-9 and TIM-3 in very heterogeneous triple-negative breast cancer (TNBC) has been significantly associated with a favorable prognosis (Yoshikawa et al., 2022).
As an immune checkpoint protein, Gal-9 has received less attention in the immune microenvironment of TNBC. Liu C. et al. (2022) identified multiple tumor immune risk score groups for TNBC, which established different types of immune microenvironments based on immune molecular markers. This research provides new insights into immunotherapy for TNBC. Previously, Ju et al. (2021) examined the relationship between Gal-9 and clinicopathological features, tumor-infiltrating lymphocyte (TIL) levels, PD-L1+ immune cells, and tumor cells in TNBC. The results suggested that increased Gal-9 expression is associated with higher immune cell infiltration and beneficial changes in terms of metastasis and other factors. Additionally, anthracyclines and taxanes are chemotherapeutic agents widely used in the adjuvant and neoadjuvant treatment of early breast cancer (Zaheed et al., 2019), Yoon et al. (2018) found a potential association between changes in PD-L1 and Gal-9 expression in TNBC and chemotherapy (anthracyclines and taxanes). A recent study showed that the anthracyclines doxorubicin and epirubicin induced Gal-9 expression via the STING/IF axis, and that the combination of chemotherapy and anti-Gal-9 produced synergistic antitumor effects (Sun et al., 2023). Although these studies did not extensively cover the drug selection process, it demonstrated the impact of cytotoxic drugs on Gal-9 expression in TNBC, providing a basis for future clinical trials evaluating combination therapies involving PD-L1 and Gal-9.
3.2.4 Lung cancer
The investigation of Gal-9 in lung cancer encompasses various types of lung cancer, including non-small cell lung cancer (NSCLC) (He et al., 2019), small cell lung cancer (SCLC) (Chen et al., 2020), lung large cell neuroendocrine carcinoma (LCNEC) (Che et al., 2022), and even the rare pulmonary sarcomatoid carcinoma (PSC) (Guo et al., 2021).
Chen et al. (2020) and Che et al. (2022) developed Gal-9-based immune risk score models to predict the recurrence prognosis of SCLC and LCNEC, respectively. Both studies, conducted in different lung cancer types, showed a significant association between Gal-9 and TIME and immune infiltration in lung cancer, particularly in stage I-III SCLC and LCNEC, where Gal-9 exhibited unique prognostic value. He et al. (2019) identified Gal-9 expression on NSCLC cells and TIL through immunohistochemistry. The expression of Gal-9 on tumor cells showed a significant correlation with survival, while Gal-9 expression on TILs was strongly associated with early postoperative recurrence. Blair et al. (2021) reported elevated Gal-9 expression in lung cancer compared to healthy controls, with differential expression observed at different stages of the disease among patients of different sexes and daily habits. Unlike other cancers, Gal-9 research in lung cancer has focused more on clinical studies, and how Gal-9 actually affects the development of lung cancer is still enigmatic in the current stage of research, and it is an urgent issue to dig out the effect of Gal-9 in lung cancer from the tissue or even single-cell level in the future.
3.2.5 Hepatocellular carcinoma (HCC)
Previous studies have demonstrated that Gal-9 is a prognostic factor for HCC with anti-metastatic potential (Gu et al., 2013). Patients with high Gal-9 expression in HCC tend to have a better prognosis. Zhang et al. (2012) utilized the Cox proportional hazard model, which indicated that negative Gal-9 expression in HCC represents a potential risk factor for patient survival.
Chronic hepatitis B virus (HBV) infection is a major risk factor for HCC (Bray et al., 2018), and identifying prognostic biomarkers for HBV-associated HCC is crucial (Mani and Andrisani, 2018). In HBV-associated HCC, Jiao et al. (2022) conducted univariate and multivariate analyses, revealing that Gal-9 could serve as an independent prognostic marker. Li et al. (2012) detected varying levels of Gal-9 expression in APC subpopulations in HCC, highlighting the role of the Gal-9-related signaling pathway in T-cell senescence in HBV-associated HCC. Furthermore, Gal-9 downregulation in HCC cells has been associated with tumor growth, migration and invasion, metastasis, postoperative recurrence, and a poor prognosis (Bacigalupo et al., 2013). A recent systemic evaluation and meta-analysis also linked low Gal-9 expression with a worse prognosis in patients with HCC (An et al., 2021). Galactose lectins have demonstrated involvement in other liver pathologies characterized by chronic inflammation and/or fibrosis (Okwor et al., 2020). While galactose lectin-based therapies have been proposed for the treatment of liver lesions like HCC, functional studies are needed to elucidate the precise molecular mechanisms by which galactose lectins contribute to HCC. Notably, although numerous studies have explored the role of Gal-9 in hepatocellular carcinoma, Kong F et al. concluded that Gal-3 outperforms Gal-9 as a novel prognostic marker in HCC, suggesting that Gal-9 expression is primarily associated with tumor progression (Kong et al., 2020).
3.2.6 Gastric cancer (GC)
In 2014, a pioneering study explored the role of Gal-9 in clinically diagnosed primary GC tissue (Yang et al., 2014). The study examined the correlation between Gal-9 expression and a variety of clinical factors in GC patients. However, no significant association was found between Gal-9 expression and distant metastasis (p > 0.05). In this study (Wang et al., 2018), more than two-fold reduction in TIM-3 expression was observed in 59% of GC tissues compared to normal tissues, which aligns with the findings of Wang Y et al. Nevertheless, no correlation between Gal-9 and TIM-3 was identified in GC. Another significant factor investigated in this context is peroxisome proliferator-activated receptor γ (PPARγ), which possesses anti-proliferative and pro-differentiation effects in various cancer types (Girnun et al., 2002; Elrod and Sun, 2008; Tontonoz and Spiegelman, 2008).
In both in vitro experiments and a systematic evaluation and meta-analysis, Gal-9 has emerged as a promising therapeutic target for the treatment of GC (Takano et al., 2016; Zhou et al., 2018). In an in vitro study conducted by Takano et al. (2016), it was visually demonstrated that Gal-9 induced apoptosis in GC by modulating miRNAs, leading to the inhibition of cancer cell proliferation. Expanding on Gal-9’s role in GC, Jin et al. (2021). Employed Gal-9 as a strategy to enhance resistance to trastuzumab in HER2-positive GC. Their findings revealed that simultaneous targeting of HER2 and WEE1 could overcome trastuzumab resistance in HER2-positive GC. Trastuzumab, known to upregulate PD-L1 via NF-kB activation (Chaganty et al., 2018; Su et al., 2018), can be counteracted by WEE1 inhibitors, which downregulate PD-L1 expression while reducing levels of Gal-9, CD163, and CTLA-4. This approach improves resistance to trastuzumab in HER2+ GC.
Additionally, a retrospective case-control study from 2018 of 2098 patients with GC revealed a noteworthy connection between low Gal-9 expression and patient prognosis (Long et al., 2018). The expression level of Gal-9 is associated with clinical features and has been acknowledged as a potential independent prognostic predictor for patients with GC (Wang R. et al., 2020).
3.2.7 Glioblastoma (GB)
In GB, Gal-9 is expressed along with multiple family partners, such as Gal-1, Gal-3, and Gal-8. The interaction of Gal-9 with their respective sugar-carrying molecules hinders the antitumor response, thereby promoting immunosuppression. While Gal-9’s immunosuppressive mechanism in GB is closely linked to TIM-3, it also plays an important role independently within GB.
Yuan et al. (2020) conducted a comprehensive analysis of 1,027 patients with glioma and found a strong upregulation of Gal-9 in GB compared to normal brain tissue. Moreover, high levels of Gal-9 expression were associated with a shorter OS in patients with low-grade gliomas. In GB tissue samples, Gal-9 expression was correlated with the presence of immunosuppressive M2-macrophages, which showed a positive correlation with immune checkpoint molecules (Knudsen et al., 2021).
3.2.8 Other solid tumors
Apart from the solid tumors mentioned earlier, Gal-9 also plays a role in cervical and vulvar aquamous cell carcinomas, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gallbladder carcinoma, and bile duct carcinoma. However, clinical research on these tumors is limited. Gal-9 exhibits distinct staining patterns in cervical and vulvar squamous cell carcinomas. While nuclear/cytoplasmic staining is typically reduced in the presence of membrane staining, both tumor types show strong expression in the nucleus and cytoplasm. This distribution pattern may be linked to the broader activity range of the Gals family (Curley et al., 2020). In esophageal adenocarcinoma (EAC) (Akashi et al., 2017), Gal-9 regulates proliferation by inducing apoptosis, autophagy, and affecting angiogenesis. It inhibits the proliferation of EAC cell lines such as OE19, OE33, SK-GT4, and OACM 5.1C, increases the expression of CCK18 and IL-8, and activates caspase-3 and caspase-9. Moreover, in esophageal squamous cell carcinoma (ESCC) (Akashi et al., 2017), Gal-9 inhibits cell proliferation through concentration-dependent activation of JNK and p38 and induces mitochondria-mediated apoptosis in ESCC cells. In gallbladder and cholangiocarcinomas (Kobayashi et al., 2015; Tadokoro et al., 2016), Gal-9 inhibits the proliferation of various cancer cells. However, in gallbladder cancer, it does not inhibit the OCUG-1 cell line, which represents a hypodifferentiated type of adenosquamous carcinoma. In both gallbladder and cholangiocarcinomas, Gal-9 induces apoptosis through different pathways. In gallbladder cancer, it increases the levels of CCK18 and phosphorylated p53. In cholangiocarcinoma, Gal-9 induces apoptosis through an intrinsic apoptotic pathway mediated by cysteinase-dependent or non-independent pathways. It decreases the phosphorylation of various growth factor receptors and increases the expression of CCK18 and cytochrome c in cholangiocarcinoma cell lines. These findings highlight the role of Gal-9 in gastrointestinal malignancies. Concurrent with the previous studies on other gastrointestinal malignancies such as gastric cancer and colorectal cancer, it becomes evident that Gal-9 is involved in the “unlimited proliferation” and “apoptosis” characteristics of these tumors.
4 Multilateral partner of TIME
The significant impact of Gal-9 on various malignant hematological diseases and solid tumors has been discussed and summarized earlier. It plays a crucial role as an immune checkpoint in multiple cancer sites, affecting various functions of tumor cells. This discussion aimed to highlight Gal-9 as an “independent entity” in the immune microenvironment.
Gal-9 has been identified as a “negative regulator of the adaptive immune response”, primarily through its binding to TIM-3, which is widely expressed in immune cells, particularly T-cells (Cedeno-Laurent and Dimitroff, 2012). The TIME is a highly complex ecosystem in which the human immune system plays a role in inhibiting tumor cell proliferation and promoting tumor cell apoptosis (Gajewski et al., 2013). Gal-9 exhibits interactions with multiple immune cells. Studies have shown that Gal-9 enhances anti-tumor immunity in mice with tumors by promoting the maturation of CD11c+ DCs, which in turn activate CD4+ TIM-3+ and CD8+ TIM-3+ T cells. In addition, Gal-9 activates plasmacytoid dendritic cell-like macrophages (PCDC), leading to the activation of NK cells. This highlights Gal-9’s role as a “Multilateral Partner” within the TIME (The figure is depicted in Figure 3).
FIGURE 3. Role of Gal-9 as a “Multilateral Partner” in the tumor immune microenvironment.
4.1 Macrophages
Macrophages play a dual role within the TIME, and TAMs are a crucial component of immune cells in the TIME. A report demonstrated that Gal-9+ TAM predicts OS, RFS, and response to adjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) (Qi et al., 2019). The expression of Gal-9 in bone marrow-derived macrophages (BMDM) is influenced by the time-dependent effects of lipopolysaccharide (LPS) simulation. Short-term LPS increases Gal-9 expression and secretion, activating the TIM-3/Gal-9 signaling pathway, which inhibits M1 polarization. On the other hand, long-term stimulation reduces Gal-9 expression and secretion, activating the TIM-3 and ultimately promoting M1 polarization (Kobayashi et al., 2015). In a report on GB, Gal-9 was highly associated with immune checkpoint molecules and M2 tumor-associated macrophages (Yuan et al., 2020). Recent research on oncogene-deficient phosphatase and tensin homolog (PTEN) GB, revealed that basement membrane cells deficient in PTEN secrete significant amounts of Gal-9 via the AKT-GSK3β-IRF1 pathway (Yuan et al., 2020). This Gal-9 secretion drives M2 polarization in macrophages by activating the TIM-3 receptor and downstream pathways. In melanoma-bearing mice, Gal-9 increases the number of macrophages, whereas Gal-9-mediated antitumor activity was not induced in macrophage-deficient mice (Nobumoto et al., 2009). Gal-9 also promotes NK cell-mediated antitumor activity by amplifying a distinct subset of macrophages that exhibit a plasma cell-like phenotype. Additionally, Gal-9 interacts with macrophages in patients with metastatic melanoma, causing CD206+ macrophages to produce increased levels of FGF2 and monocyte chemotactic protein-1 (MCP-1) while reducing macrophage-derived chemokines (MDC) (Enninga et al., 2018). This suggests that Gal-9 plays a role in promoting the production of angiogenic chemokines in malignant melanoma through its interaction with macrophages. Although Gal-9 polarizes macrophages differently depending on the available conditions, we believe that the role of Gal-9 and macrophages within this environment is consistent. TAMs with high expression of Gal-9 inhibit tumor cell activity in the absence of intervention by other factors.
4.2 NK cells
Differences in the effector function of Gal-9+ NK cells between mice and humans should be considered in different physiological and pathological conditions. A recent study revealed the expansion of Gal-9+ NK cells in the tumor tissue of melanoma mice (Rahmati et al., 2023). The authors of the study, Meggyes et al. (2021), demonstrated that Gal-9 intervention led to the production of IL-10 by NK-92MI cells. IL-10 is a potent immunosuppressive cytokine that facilitates tumor cell evasion from APCs and impairs helper T cell-mediated immune surveillance. Consequently, this suggests that the cytotoxic effect of NK cells is reduced primarily through secondary mechanisms (D'Andrea et al., 1993). This finding has inspired further investigation to determine the precise function induced by the increased IL-10 levels following Gal-9 treatment.
4.3 Dendritic cells
Alterations in the activity and phenotype of dendritic cells play a role in the progression of various diseases. For instance, in patients with endometriosis, the accumulation of myeloid DCs expressing Gal-9 and plasmacytoid DCs in the peritoneal fluid is considered a characteristic feature of immune regulation (Suszczyk et al., 2023). Similarly, in GB, Gal-9 serves as a marker of immune regulation: After Gal-9 intervention, do not secrete IL-10 but instead produce IL-2 (Liberal et al., 2012). Gal-9 induces the maturation of DCs and promotes Th1 immune responses in adaptive immunity (Liberal et al., 2012). DCs can generate IFN-β, and the combined effect of IFN-β and IFN-γ increases the expression of Gal-9 in APCs, including B cells, DCs, and TAMs. This upregulation of Gal-9 inhibits anti-tumor responses by inducing T cell death (Yang et al., 2021).
4.4 Lymphocytes
In the context of adaptive immunity, CD4+ T cells differentiate into two subsets, namely, helper T cells 1 (Th1 cells) and helper T cells 2 (Th2 cells), in response to different antigenic stimuli (Mosmann and Coffman, 1989). Both CD4+ and CD8+ T cells are sensitive to Gal-9-induced cell death, but CD8+ cytotoxic T cells are considered more sensitive than CD4+ T cells (Yang et al., 2021). Th1 cells produce IL-2 and IFN-γ, which induce a delayed hypersensitivity response and promote immunity (Paul and Seder, 1994). On the other hand, Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which are involved in immunoglobulin G1 (IgG1) and IgE production as well as eosinophilic inflammation (Paul and Seder, 1994). The cytokines produced by Th1 and Th2 cells have opposing roles in immune regulation and can cross-regulate and exhibit mutual functional inhibition (Street and Mosmann, 1991). However, dysregulation of Th1 and Th2 responses can lead to pathological consequences. Overactive Th1 responses may cause organ-specific autoimmune diseases such as type I diabetes and multiple sclerosis (Romagnani, 1994; Kamradt and Mitchison, 2001), while uncontrolled Th2 responses are associated with allergies and sensitivities (Sher and Coffman, 1992; Abbas et al., 1996).
Functional studies have demonstrated that Gal-9 induces Th1 cell death via TIM-3, but not Th2 cell death (Zhu et al., 2005). In immunized mice, the injection of Gal-9 substantially reduces the number of IFN-γ-producing Th1 cells (Zhu et al., 2005). In studies related to AML (Kashio et al., 2003), AML cells impaired the anticancer activity of cytotoxic lymphocytes, including NK cells and T lymphocytes. The mechanism of T-cell death induced by Gal-9 has been investigated, particularly in leukemic T-cell lines. High doses of Gal-9 induce apoptosis in various T-cell leukemia cell lines in a dose-dependent manner, depending on the presence of CRDs in their structure. Interestingly, T cells themselves express and release the Gal-9 isoforms Gal-9 (M) and Gal-9 (L), and the sensitivity of T cells to Gal-9 is negatively correlated with their expression of Gal-9 (Hirashima, 2000; Chabot et al., 2002). Gal-9 induces T cell death in a variety of ways (Wiersma et al., 2013), including caspase-dependent apoptosis, Ca2+/Calpain activation, release of pro-apoptotic mitochondrial factors, or inhibition of cell cycle progression. In 2018, Giovannone et al. (2018) demonstrated the role of Gal-9 as an intrinsic B cell regulator of B cell receptor signaling and activation and that naive and memory B cells strongly bind Gal-9, and naive B cells express Gal-9 in blood and lymphoid tissue. Notably, CD45 was identified as the primary receptor for Gal-9 on naïve B cells, and binding of Gal-9 to CD45 activates inhibitory signaling pathways via the Lyn-CD22-SHP-1 pathway. Gal-9 functions as an inhibitor of B-cell receptor signaling, and its downregulation may contribute to a lower activation threshold of memory B cells.
5 Prospect of Gal-9 in the tumor immuno therapy
5.1 Gal-9 and its ligand TIM-3: the future of tumor immunotherapy
Gals are considered largely as modulators of the tumor immune response (Yang et al., 2021). There is growing interest in the future development of effective methods to modulate the effects of Gal-9 on tumors and autoimmunity. Previously, we identified co-regulatory pathways associated with Gal-9 in certain tumors, such as Gal-9/TIM-3. The Gal-9/TIM-3 pathway was described as a critical stimulatory loop for leukemic stem cells by Kikushige et al. This loop leads to Th1-mediated immune dysfunction and T cell apoptosis.
The dysregulation of immune responses plays a crucial role in the development of AML/MDS, opening up new possibilities for immunotherapy (Gallazzi et al., 2022). Sabatolimab (MBG453), although an inhibitor of TIM-3, disrupts the interaction between TIM-3 and Gal-9, showing promising results in the treatment of AML/MDS. A study utilizing multi-parameter flow cytometry analyzed peripheral blood and bone marrow biopsy specimens from 26 patients with AML at the time of diagnosis and after induction therapy (Dama et al., 2019). The study found that targeting the Gal9/TIM-3 pathway in combination with induction chemotherapy could enhance the likelihood of achieving complete remission in AML.
Earlier studies have shown that Gal-9 binds to TIM-3 and induces apoptosis by inducing TH1 cell death via intracellular calcium flow. This would therefore lead to induction of immune tolerance and suppression of TH1 and TH17 responses (Zhu et al., 2005). In breast cancer, where breast cancer cells do not secrete Gal-9, a study by Yasinska et al. (2019) confirmed the higher expression levels of Gal-9 and TIM-3 were found in breast cancer tissues compared to healthy breast tissues, and activation of the FLRT3/LPHN/TIM-3/Gal-9 pathway specifically promoted the translocation of Gal-9 on the surface of the tumor cell surface.
Notably, Gal-9 can exert its function through the release of extracellular vesicles. A noteworthy study demonstrated that Gal-9-enriched exosomes derived from GB impair the function of dendritic cells (DCs) and CD8+ T cells by binding to TIM-3, thereby facilitating tumor progression (Wang M. et al., 2020). The activity of exosomal Gal-9 on DCs is dependent on TIM-3, and knocking down TIM-3 in DCs restores their function and activation. As a result, it has been suggested as a potential therapeutic target to disrupt cell-cell interactions and exosome communication.
On the other hand, despite efforts to address the limitations of PD-1/PD-L1 immunotherapy with plant-derived compounds, drug resistance remains a challenging issue in current clinical oncology treatment (Liu K. et al., 2022). In a study by Yang et al. (2021), it was found that PD-1 can bind to Gal-9 on C-CRD, forming a competitive relationship with Gal-9/TIM-3. The formation of TIM-3/Gal-9/PD-1 complexes contributes to the persistence of PD-1+ TIM-3+ T cells and weakens Gal-9/TIM-3-induced cell death. These findings shed light on the intricate battle between cancer cells and the immune system. Based on these key observations and the significant anti-cancer activity of anti-Gal-9 antibodies, Gal-9 has become an attractive target for cancer therapy and Gal-9, either alone or in combination with TIM-3, plays a crucial role in maintaining immunosuppression within the tumor microenvironment.
5.2 Gal-9-related immune combination therapies: new directions in tumor immunotherapy
The diverse range of chemotherapy drugs can effectively enhance the efficacy and response of cancer patients, indicating that the combination of multiple immune checkpoints may address the limitations of single immune checkpoint inhibitors (Liu J. et al., 2022). Research suggests that Gal-9 is actually a protein that facilitates the escape of cancer from immune surveillance (Wiersma et al., 2015). The study by Yang, R., et al. evaluated the potential of Gal-9 inhibition in tumor therapy from a T cell perspective, where the preferential killing of T cells over cancer cells by anti-Gal-9 antibodies might contribute to tumor immune escape (Yang et al., 2021).
Although immunotherapies targeting T cells have shown promising clinical results, only a small percentage of patients have responded. The failure of monotherapy in many patients could be attributed to additional immune evasion mechanisms (Dempke et al., 2017). Notably, positive expression of PD-L1 in cervical and ectopic squamous cell carcinomas is often accompanied by the expression of TIM-3 and Gal-9, indicating the presence of checkpoint-based immune evasion mechanisms (Curley et al., 2020). Within the TIME, Gal-9 is found in nearly all immune cells and exhibits membranous expression in invasive and intraepithelial tumors. In invasive carcinomas, there is no significant difference in the expression of membranous TIM-3 or Gal-9 between cervical and vulvar locations. Furthermore, all PD-L1-positive squamous cell carcinomas co-express TIM-3 and Gal-9, suggesting the potential of combination therapies involving immune checkpoint inhibitors for future cervical cancer treatment. Exploring the interrelationship between different immune checkpoints may provide valuable insight in the fight against immune escape.
The use of Gal-9 ligands, such as lactose, can help regulate the inhibitory receptors PD-1 and TIM-3. Undoubtedly, new therapies centered around anti-Gal-9 will soon be proposed (Bailly et al., 2021). As an endoplasmic reticulum membrane-binding protein, stimulator of interferon genes (STING)’s activation of oligomers triggers downstream events that promote immune response activation (Yu et al., 2022). Recent findings by Shuang Zheng et al. (Zheng et al., 2023) have revealed an important mechanism by which Gal-9 mediates tumor immune escape through the STING/IFN-β signaling pathway. This, along with the research by Yang et al. (2021), suggests a novel combination strategy involving anti-Gal-9, including cases resistant to PD-1/PD- L1 blockade. It is worth noting that the clinical emergence of combination therapy involving Gal-9 and PD-L1 has shown promising results. Studies have demonstrated that the combination therapy of Gal-9 and PD-L1 can enhance the effectiveness of anti-PD-L1 antibody therapy in patients with pancreatic ductal adenocarcinoma (Li et al., 2023). In this context, lactose or its derivatives, as well as functionally equivalent products, may also hold potential utility. Not coincidentally, a recent study found that Gal-9 upregulation by anthracyclines is a novel mechanism mediating tumor immune escape, and Sun X et al. identified the combination of adriamycin and anti-Gal-9 therapies as a promising strategy for cancer treatment (Sun et al., 2023). Additionally, Choukrani G et al. found that gal-9 could be of therapeutic interest for (azacitidine-resistant) AML (Choukrani et al., 2023). The combination of Gal-9 with azacitidine induced more cell death compared to either azacitidine or Gal-9 alone.
6 Discussion
Gals have received increasing attention in the last decade due to their crucial role in tumorigenesis and cancer progression. This group of proteins exhibits diverse functionalities both inside and outside cells, leading to their varying impact on cancer development (Li et al., 2021). Among the Gals family, Gal-9 has been the focus of numerous studies, particularly regarding its role as a ligand for TIM-3 in various diseases.
It is worth mentioning that the literature we included in the previous section involved a Meta-analysis study of 4,166 HCC patients (An et al., 2021) and a multivariate analysis of 2,233 patients with multiple cancers (Irie et al., 2005; Yamauchi et al., 2006; Melief et al., 2017; Curley et al., 2020; Yuan et al., 2020), which clearly demonstrated the evidence for Gal-9 as an independent influencing factor in pan-cancer from an evidence-based medical perspective. Based on these evidences, we examined the relationship between Gal-9 and clinically common malignant hematologic and solid tumors. We explored the potential of Gal-9 as a predictive biomarker for the response to immune checkpoint blockade therapy, which holds promise for further clinical applications.
In fact, our study found that Gal-9 expression can be detected in different tumor tissues and cells, and most of the studies confirmed that there is a correlation between the variability of Gal-9 expression in tumors and the degree of malignancy of tumors. During the benign-to-malignant transition, a trend toward Gal-9 downregulation was demonstrated at both the RNA and protein levels. Studies have shown that detection of Gal-9 expression is superior to detection of lymph node invasion in diagnosing the presence of metastasis in breast cancer tissue specimens. In addition, patients with high Gal-9 expression had significantly higher survival than those with low Gal-9 expression, and similar results were seen in studies of melanoma, cervical squamous cell carcinoma, and hepatocellular carcinoma. These preliminary findings confirm that Gal-9 can play a role in tumor therapy and warrants further study in other cancers. For the study of the relationship between Gal-9 and tumors, in addition to exogenous interference with Gal-9 expression, Gal-9 protein itself can also be applied to target specific receptors or modulate tumor factor interactions, which should also take into account the different biological roles played by different Gal-9 isoforms.
An increasing number of studies are shedding light on the effects of Gal-9 on the immune components of TIME, and these studies aim to unravel the mechanisms by which Gal-9 coordinates the immune status of the body. Although it is difficult to establish a systematic framework of Gal-9’s impact on the tumor immune microenvironment as of the current relevant studies, these results provide ideas for future translation of Gal-9 into clinical research to some extent.
On the other hand, we highlight the potential of Gal-9-based combination immunotherapy in the clinic. In addition, Immune escape is an important hallmark of many tumors. We believe that Gal-9’s ability to counteract tumor cell evasion from immune surveillance may be influenced by tumor heterogeneity and its varying benefits for immunotherapy. Interestingly, studies on “unlimited proliferation” and “apoptosis”, also tumor hallmarks, have found that these two “hallmarks” are concentrated in gastrointestinal tumors (Tang et al., 2022), including colorectal cancers (Sasidharan Nair et al., 2018; Blair et al., 2021), EAC (Akashi et al., 2017), ESCC (Chiyo et al., 2019), gallbladder (Tadokoro et al., 2016), and bile duct (Kobayashi et al., 2015).
As previously mentioned, although the “Partnership” between Gal-9 and TIM-3 is being explored in cancer research, with studies on Gal-9 in malignant hematological diseases and solid tumors primarily focus on the Gal-9/TIM-3 pathway. Further investigations are needed to fully understand the versatility of Gal-9 itself in cancer. Gal-1, -3, -8, and -9, along with their respective sugar-carrying molecules, interact to inhibit antitumor responses and promote immunosuppression in specific cancer types. However, the antitumor effects of targeted Gal members do not solely rely on their downstream pathways. TIM-3, as a receptor for Gal-9, is widely expressed in immune cells, particularly T cells, while other immune checkpoints are also recognized by Gal-9. Therefore, exclusively focusing on the Gal-9/TIM-3 pathway in targeting studies may limit our understanding and overlook the independent properties of Gal-9 and TIM-3 themselves.
Considering the complex structures and functions of Gal-9 and TIM-3, it is possible that Gal-9 could serve as an effective independent therapeutic target in malignant hematological diseases and malignancies in the future. While the tumor microenvironment can be likened to a composite “soil,” different immune cells possess their own distinct characteristics. In this regard, we aim to establish a Gal-9-associated complex immune microenvironmental crosstalk network in the future by investigating the interactions of Gal-9 with a variety of immune cells.
Gal-9 has aroused great interest since its discovery. Early in the study, its characteristic function was that it could induce eosinophil aggregation and activation, and as the study continued, it also played a role in the regulation of cell differentiation, adhesion, apoptosis, inflammatory response, and anti-inhibition of rejection. Autoimmune diseases, inflammatory reactions, transplant rejection, and malignant blood diseases are all closely related to Gal-9. Even in recent studies, Gal-9 has been found to be involved in the antiviral response in diseases such as AIDS and COVID-19 (Iwasaki-Hozumi et al., 2023; Thorman et al., 2023). In recent years, more and more researchers have turned their attention to the multifaceted regulation of tumor cells by Gal-9: in various types of tumors, Gal-9 crosstalks with tumor cells by regulating apoptosis, metastasis, immune escape, and angiogenesis. Unfortunately, the regulation of tumorigenesis and development by Gal-9 is achieved through multiple mechanisms, and it is difficult to even summarize the commonality of the specific mechanisms of Gal-9 on tumors, except for the exploration of the Gal-9/TIM-3 pathway, and the application of Gal-9 to the clinic is yet to be further matured by systematic studies.
Given the intricate role of Gal-9 in different tumor types and within the tumor microenvironment, future research efforts should focus on exploring its upstream non-coding RNA and downstream target genes. Investigating these aspects will be crucial in understanding the molecular mechanisms associated with Gal-9 in tumor development. Additionally, bioengineering of recombinant Gal-9 has attracted interest in recent years, with a subset of reports suggesting that Gal-9 can interact homotypically and heterotypically with other members of the Gals in a CRD-dependent manner, and that such interactions can have enhanced affinity for the target. Furthermore, combining targeted Gal-9 therapy with immunotherapy or chemotherapy that involves checkpoint blockade may offer a potential treatment approach for tumors enriched with Gal-9. This synergistic approach has the potential to enhance treatment efficacy and improve outcomes for patients with Gal-9-associated tumors. In conclusion, the complex role that Gal-9 plays in tumors expands the knowledge of galactoglucan lectins, and although the role of this character is not clear from current studies, we cannot deny its potential in future tumor immunotherapy.
Author contributions
MZ: Writing–original draft. CL: Writing–original draft. YL: Visualization, Writing–review and editing. HL: Visualization, Writing–review and editing. WZ: Visualization, Writing–review and editing.JL: Visualization, Writing–review and editing. LW: Writing–review and editing. CS: Conceptualization, Funding acquisition, Supervision, Writing–review and editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (81973677, 82174222, 82305000), Natural Science Foundation of Shandong Province (ZR2021LZY015) and Weifang Science and Technology Development Plan (2022GX008).
Acknowledgments
Thanks to biorender (www.biorender.com) for the drawing material.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aanhane, E., Schulkens, I. A., Heusschen, R., Castricum, K., Leffler, H., Griffioen, A. W., et al. (2018). Different angioregulatory activity of monovalent galectin-9 isoforms. Angiogenesis 21 (3), 545–555. doi:10.1007/s10456-018-9607-8
Abbas, A. K., Murphy, K. M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. Nature 383 (6603), 787–793. doi:10.1038/383787a0
Akashi, E., Fujihara, S., Morishita, A., Tadokoro, T., Chiyo, T., Fujikawa, K., et al. (2017). Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. Oncol. Rep. 38 (1), 506–514. doi:10.3892/or.2017.5689
An, Y., Xu, S., Liu, Y., Xu, X., Philips, C. A., Chen, J., et al. (2021). Role of galectins in the liver diseases: a systematic review and meta-analysis. Front. Med. (Lausanne) 8, 744518. doi:10.3389/fmed.2021.744518
Asayama, T., Tamura, H., Ishibashi, M., Kuribayashi-Hamada, Y., Onodera-Kondo, A., Okuyama, N., et al. (2017). Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget 8 (51), 88904–88917. doi:10.18632/oncotarget.21492
Ashraf, G. M., Perveen, A., Tabrez, S., Jabir, N. R., Damanhouri, G. A., Zaidi, S. K., et al. (2015). Altered galectin glycosylation: potential factor for the diagnostics and therapeutics of various cardiovascular and neurological disorders. Adv. Exp. Med. Biol. 822, 67–84. doi:10.1007/978-3-319-08927-0_10
Ashraf, G. M., Perveen, A., Zaidi, S. K., Ahmad, A., Shakil, S., Firoz, C. K., et al. (2017). Galectins-A potential target for cardiovascular therapy. Curr. Vasc. Pharmacol. 15 (4), 296–312. doi:10.2174/1570161115666170201113046
Bacigalupo, M. L., Manzi, M., Rabinovich, G. A., and Troncoso, M. F. (2013). Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J. Gastroenterol. 19 (47), 8831–8849. doi:10.3748/wjg.v19.i47.8831
Bailly, C., Thuru, X., and Quesnel, B. (2021). Modulation of the gal-9/TIM-3 immune checkpoint with alpha-lactose. Does anomery of lactose matter? Cancers (Basel) 13 (24), 6365. doi:10.3390/cancers13246365
Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., et al. (1994a). Galectins: a family of animal beta-galactoside-binding lectins. Cell 76 (4), 597–598. doi:10.1016/0092-8674(94)90498-7
Barondes, S. H., Cooper, D. N., Gitt, M. A., and Leffler, H. (1994b). Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269 (33), 20807–20810. doi:10.1016/s0021-9258(17)31891-4
Blair, B. B., Funkhouser, A. T., Goodwin, J. L., Strigenz, A. M., Chaballout, B. H., Martin, J. C., et al. (2021). Increased circulating levels of galectin proteins in patients with breast, colon, and lung cancer. Cancers (Basel) 13 (19), 4819. doi:10.3390/cancers13194819
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394–424. doi:10.3322/caac.21492
Cedeno-Laurent, F., and Dimitroff, C. J. (2012). Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J. 29 (8-9), 619–625. doi:10.1007/s10719-012-9379-0
Chabot, S., Kashio, Y., Seki, M., Shirato, Y., Nakamura, K., Nishi, N., et al. (2002). Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 12 (2), 111–118. doi:10.1093/glycob/12.2.111
Chaganty, B. K. R., Qiu, S., Gest, A., Lu, Y., Ivan, C., Calin, G. A., et al. (2018). Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 430, 47–56. doi:10.1016/j.canlet.2018.05.009
Chaudhary, S., Rawat, S., Kulkarni, A., Bilgrami, A. L., Perveen, A., Alghamdi, B. S., et al. (2022). Galectins-potential therapeutic targets for neurodegenerative disorders. Int. J. Mol. Sci. 23 (19), 11012. doi:10.3390/ijms231911012
Che, Y., Luo, Z., Cao, Y., Wang, J., Xue, Q., Sun, N., et al. (2022). Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma and its usefulness in immunotherapy. Int. J. Biol. Sci. 18 (15), 5913–5927. doi:10.7150/ijbs.76936
Chen, P., Zhang, L., Zhang, W., Sun, C., Wu, C., He, Y., et al. (2020). Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer. J. Immunother. Cancer 8 (2), e001391. doi:10.1136/jitc-2020-001391
Chen, T. C., Chen, C. H., Wang, C. P., Lin, P. H., Yang, T. L., Lou, P. J., et al. (2017). The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment. Sci. Rep. 7 (1), 10349. doi:10.1038/s41598-017-10386-y
Chiyo, T., Fujita, K., Iwama, H., Fujihara, S., Tadokoro, T., Ohura, K., et al. (2019). Galectin-9 induces mitochondria-mediated apoptosis of esophageal cancer in vitro and in vivo in a xenograft mouse model. Int. J. Mol. Sci. 20 (11), 2634. doi:10.3390/ijms20112634
Cho, S. J., Kook, M. C., Lee, J. H., Shin, J. Y., Park, J., Bae, Y. K., et al. (2015). Peroxisome proliferator-activated receptor gamma upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. Int. J. Cancer 136 (4), 810–820. doi:10.1002/ijc.29056
Chou, F. C., Chen, H. Y., Kuo, C. C., and Sytwu, H. K. (2018). Role of galectins in tumors and in clinical immunotherapy. Int. J. Mol. Sci. 19 (2), 430. doi:10.3390/ijms19020430
Choukrani, G., Visser, N., Ustyanovska Avtenyuk, N., Olthuis, M., Marsman, G., Ammatuna, E., et al. (2023). Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance. Cell Death Discov. 9 (1), 228. doi:10.1038/s41420-023-01515-w
Cristiani, C. M., Turdo, A., Ventura, V., Apuzzo, T., Capone, M., Madonna, G., et al. (2019). Accumulation of circulating CCR7(+) natural killer cells marks melanoma evolution and reveals a CCL19-dependent metastatic pathway. Cancer Immunol. Res. 7 (5), 841–852. doi:10.1158/2326-6066.CIR-18-0651
Curley, J., Conaway, M. R., Chinn, Z., Duska, L., Stoler, M., and Mills, A. M. (2020). Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Mod. Pathol. 33 (6), 1182–1192. doi:10.1038/s41379-019-0433-3
Dama, P., Tang, M., Fulton, N., Kline, J., and Liu, H. (2019). Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J. Immunother. Cancer 7 (1), 175. doi:10.1186/s40425-019-0611-3
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., and Trinchieri, G. (1993). Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178 (3), 1041–1048. doi:10.1084/jem.178.3.1041
Dempke, W. C. M., Fenchel, K., Uciechowski, P., and Dale, S. P. (2017). Second- and third-generation drugs for immuno-oncology treatment-The more the better? Eur. J. Cancer 74, 55–72. doi:10.1016/j.ejca.2017.01.001
Elrod, H. A., and Sun, S. Y. (2008). PPARgamma and apoptosis in cancer. PPAR Res. 2008, 704165. doi:10.1155/2008/704165
Enninga, E. A. L., Chatzopoulos, K., Butterfield, J. T., Sutor, S. L., Leontovich, A. A., Nevala, W. K., et al. (2018). CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment. J. Pathol. 245 (4), 468–477. doi:10.1002/path.5093
Gajewski, T. F., Schreiber, H., and Fu, Y. X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (10), 1014–1022. doi:10.1038/ni.2703
Gallazzi, M., Ucciero, M. A. M., Faraci, D. G., Mahmoud, A. M., Al Essa, W., Gaidano, G., et al. (2022). New Frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes. Int. J. Mol. Sci. 23 (14), 7542. doi:10.3390/ijms23147542
Giovannone, N., Liang, J., Antonopoulos, A., Geddes Sweeney, J., King, S. L., Pochebit, S. M., et al. (2018). Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans. Nat. Commun. 9 (1), 3287. doi:10.1038/s41467-018-05770-9
Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., et al. (2002). APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl. Acad. Sci. U. S. A. 99 (21), 13771–13776. doi:10.1073/pnas.162480299
Gleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., et al. (2012). Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119 (13), 3064–3072. doi:10.1182/blood-2011-06-360321
Goncalves Silva, I., Yasinska, I. M., Sakhnevych, S. S., Fiedler, W., Wellbrock, J., Bardelli, M., et al. (2017). The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine 22, 44–57. doi:10.1016/j.ebiom.2017.07.018
Gu, C. J., Wu, H., Sheng, C. y., and Ni, Q. c. (2013). Expression and prognostic value of galectin-9 in hepatocellular carcinoma patients. Zhonghua Yi Xue Za Zhi 93 (26), 2025–2028. doi:10.3760/cma.j.issn.0376-2491.2013.26.003
Guo, H., Li, B., Diao, L., Wang, H., Chen, P., Jiang, M., et al. (2021). An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). Oncoimmunology 10 (1), 1947665. doi:10.1080/2162402X.2021.1947665
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100 (1), 57–70. doi:10.1016/s0092-8674(00)81683-9
He, Y., Jia, K., Dziadziuszko, R., Zhao, S., Zhang, X., Deng, J., et al. (2019). Galectin-9 in non-small cell lung cancer. Lung Cancer 136, 80–85. doi:10.1016/j.lungcan.2019.08.014
Hirashima, M. (2000). Ecalectin/galectin-9, a novel eosinophil chemoattractant: its function and production. Int. Arch. Allergy Immunol. 122 (Suppl. 1), 6–9. doi:10.1159/000053623
Hirashima, M., Kashio, Y., Nishi, N., Yamauchi, A., Imaizumi, T. a., Kageshita, T., et al. (2002). Galectin-9 in physiological and pathological conditions. Glycoconj J. 19 (7-9), 593–600. doi:10.1023/B:GLYC.0000014090.63206.2f
Holderried, T. A. W., de Vos, L., Bawden, E. G., Vogt, T. J., Dietrich, J., Zarbl, R., et al. (2019). Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clin. Epigenetics 11 (1), 161. doi:10.1186/s13148-019-0752-8
Irie, A., Yamauchi, A., Kontani, K., Kihara, M., Liu, D., Shirato, Y., et al. (2005). Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 11 (8), 2962–2968. doi:10.1158/1078-0432.CCR-04-0861
Iwasaki-Hozumi, H., Maeda, Y., Niki, T., Chagan-Yasutan, H., Bai, G., Matsuba, T., et al. (2023). Plasma N-cleaved galectin-9 is a surrogate marker for determining the severity of COVID-19 and monitoring the therapeutic effects of tocilizumab. Int. J. Mol. Sci. 24 (4), 3591. doi:10.3390/ijms24043591
Jabbour, E., Short, N. J., Jain, N., Haddad, F. G., Welch, M. A., Ravandi, F., et al. (2023). The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J. Hematol. Oncol. 16 (1), 22. doi:10.1186/s13045-023-01409-5
Jiao, J., Jiao, D., Yang, F., Zhang, J., Li, Y., Han, D., et al. (2022). Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma. Aging (Albany NY) 14 (4), 1879–1890. doi:10.18632/aging.203909
Jin, M. H., Nam, A. R., Bang, J. H., Oh, K. S., Seo, H. R., Kim, J. M., et al. (2021). WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer 24 (5), 1003–1020. doi:10.1007/s10120-021-01176-7
Ju, M. H., Byun, K. D., Park, E. H., Lee, J. H., and Han, S. H. (2021). Association of galectin 9 expression with immune cell infiltration, programmed cell death ligand-1 expression, and patient's clinical outcome in triple-negative breast cancer. Biomedicines 9 (10), 1383. doi:10.3390/biomedicines9101383
Kageshita, T., Kashio, Y., Yamauchi, A., Seki, M., Abedin, M. J., Nishi, N., et al. (2002). Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 99 (6), 809–816. doi:10.1002/ijc.10436
Kamradt, T., and Mitchison, N. A. (2001). Tolerance and autoimmunity. N. Engl. J. Med. 344 (9), 655–664. doi:10.1056/NEJM200103013440907
Kapetanakis, N. I., and Busson, P. (2023). Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies. Front. Immunol. 14, 1145268. doi:10.3389/fimmu.2023.1145268
Kashio, Y., Nakamura, K., Abedin, M. J., Seki, M., Nishi, N., Yoshida, N., et al. (2003). Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 170 (7), 3631–3636. doi:10.4049/jimmunol.170.7.3631
Kikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh-Tabrizi, S., Shima, T., Takayanagi, S. i., et al. (2015). A TIM-3/gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17 (3), 341–352. doi:10.1016/j.stem.2015.07.011
Knudsen, A. M., Rudkjøbing, S. J., Sørensen, M. D., Dahlrot, R. H., and Kristensen, B. W. (2021). Expression and prognostic value of the immune checkpoints galectin-9 and PD-L1 in glioblastomas. J. Neuropathol. Exp. Neurol. 80 (6), 541–551. doi:10.1093/jnen/nlab041
Kobayashi, K., Morishita, A., Iwama, H., Fujita, K., Okura, R., Fujihara, S., et al. (2015). Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol. Rep. 34 (4), 1761–1770. doi:10.3892/or.2015.4197
Kong, F., Jin, M., Cao, D., Jia, Z., Liu, Y., and Jiang, J. (2020). Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ 8, e9949. doi:10.7717/peerj.9949
Lee, M., Hamilton, J. A. G., Talekar, G. R., Ross, A. J., Michael, L., Rupji, M., et al. (2022). Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. Nat. Commun. 13 (1), 1157. doi:10.1038/s41467-022-28839-y
Li, C. H., Hsu, T. I., Chang, Y. C., Chan, M. H., Lu, P. J., and Hsiao, M. (2021). Stationed or relocating: the seesawing EMT/MET determinants from embryonic development to cancer metastasis. Biomedicines 9 (9), 1265. doi:10.3390/biomedicines9091265
Li, E., Xu, J., Chen, Q., Zhang, X., Xu, X., and Liang, T. (2023). Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3), 135–147. doi:10.2217/imt-2021-0075
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., et al. (2012). Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56 (4), 1342–1351. doi:10.1002/hep.25777
Liberal, R., Grant, C. R., Holder, B. S., Ma, Y., Mieli-Vergani, G., Vergani, D., et al. (2012). The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. Hepatology 56 (2), 677–686. doi:10.1002/hep.25682
Liu, C., Li, Y., Xing, X., Zhuang, J., Wang, J., Wang, C., et al. (2022a). Immunogenomic landscape analyses of immune molecule signature-based risk panel for patients with triple-negative breast cancer. Mol. Ther. Nucleic Acids 28, 670–684. doi:10.1016/j.omtn.2022.04.034
Liu, J., Yu, Y., Liu, C., Gao, C., Zhuang, J., Liu, L., et al. (2022c). Combinatorial regimens of chemotherapeutic agents: a new perspective on raising the heat of the tumor immune microenvironment. Front. Pharmacol. 13, 1035954. doi:10.3389/fphar.2022.1035954
Liu, K., Sun, Q., Liu, Q., Li, H., Zhang, W., and Sun, C. (2022b). Focus on immune checkpoint PD-1/PD-L1 pathway: new advances of polyphenol phytochemicals in tumor immunotherapy. Biomed. Pharmacother. 154, 113618. doi:10.1016/j.biopha.2022.113618
Long, B., Yu, Z., Zhou, H., Ma, Z., Ren, Y., Zhan, H., et al. (2018). Clinical characteristics and prognostic significance of galectins for patients with gastric cancer: a meta-analysis. Int. J. Surg. 56, 242–249. doi:10.1016/j.ijsu.2018.06.033
Mani, S. K. K., and Andrisani, O. (2018). Hepatitis B virus-associated hepatocellular carcinoma and hepatic cancer stem cells. Genes (Basel) 9 (3), 137. doi:10.3390/genes9030137
Marasco, L. E., and Kornblihtt, A. R. (2023). The physiology of alternative splicing. Nat. Rev. Mol. Cell Biol. 24 (4), 242–254. doi:10.1038/s41580-022-00545-z
Meggyes, M., Nagy, D. U., Balassa, T., Godony, K., Peterfalvi, A., Szereday, L., et al. (2021). Influence of galectin-9 treatment on the phenotype and function of NK-92MI cells in the presence of different serum supplements. Biomolecules 11 (8), 1066. doi:10.3390/biom11081066
Melief, S. M., Visconti, V. V., Visser, M., van Diepen, M., Kapiteijn, E. H. W., van den Berg, J. H., et al. (2017). Long-term survival and clinical benefit from adoptive T-cell transfer in stage IV melanoma patients is determined by a four-parameter tumor immune signature. Cancer Immunol. Res. 5 (2), 170–179. doi:10.1158/2326-6066.CIR-16-0288
Morishita, A., Nomura, K., Tani, J., Fujita, K., Iwama, H., Takuma, K., et al. (2021). Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo. Oncol. Rep. 45 (6), 105. doi:10.3892/or.2021.8056
Mosmann, T. R., and Coffman, R. L. (1989). TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145–173. doi:10.1146/annurev.iy.07.040189.001045
Nagae, M., Nishi, N., Murata, T., Usui, T., Nakamura, T., Wakatsuki, S., et al. (2006). Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 281 (47), 35884–35893. doi:10.1074/jbc.M606648200
Nagae, M., Nishi, N., Nakamura-Tsuruta, S., Hirabayashi, J., Wakatsuki, S., and Kato, R. (2008). Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue. J. Mol. Biol. 375 (1), 119–135. doi:10.1016/j.jmb.2007.09.060
Nobumoto, A., Nagahara, K., Oomizu, S., Katoh, S., Nishi, N., Takeshita, K., et al. (2008). Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18 (9), 735–744. doi:10.1093/glycob/cwn062
Nobumoto, A., Oomizu, S., Arikawa, T., Katoh, S., Nagahara, K., Miyake, M., et al. (2009). Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin. Immunol. 130 (3), 322–330. doi:10.1016/j.clim.2008.09.014
Okwor, C. I. A., Oh, J. S., Crawley, A. M., Cooper, C. L., and Lee, S. H. (2020). Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis. iScience 23 (9), 101513. doi:10.1016/j.isci.2020.101513
Pally, D., Banerjee, M., Hussain, S., Kumar, R. V., Petersson, A., Rosendal, E., et al. (2022). Galectin-9 signaling drives breast cancer invasion through extracellular matrix. ACS Chem. Biol. 17 (6), 1376–1386. doi:10.1021/acschembio.1c00902
Pang, N., Alimu, X., Chen, R., Muhashi, M., Ma, J., Chen, G., et al. (2021). Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 35 (7), e21556. doi:10.1096/fj.202100013R
Paul, W. E., and Seder, R. A. (1994). Lymphocyte responses and cytokines. Cell 76 (2), 241–251. doi:10.1016/0092-8674(94)90332-8
Qi, Y., Chang, Y., Wang, Z., Chen, L., Kong, Y., Zhang, P., et al. (2019). Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. Cancer Immunol. Immunother. 68 (12), 2067–2080. doi:10.1007/s00262-019-02429-2
Rahmati, A., Bigam, S., and Elahi, S. (2023). Galectin-9 promotes natural killer cells activity via interaction with CD44. Front. Immunol. 14, 1131379. doi:10.3389/fimmu.2023.1131379
Romagnani, S. (1994). Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12, 227–257. doi:10.1146/annurev.iy.12.040194.001303
Ruvolo, P. P. (2019). Galectins as regulators of cell survival in the leukemia niche. Adv. Biol. Regul. 71, 41–54. doi:10.1016/j.jbior.2018.09.003
Sasidharan Nair, V., Toor, S. M., Taha, R. Z., Shaath, H., and Elkord, E. (2018). DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin. Epigenetics 10 (1), 104. doi:10.1186/s13148-018-0539-3
Sato, M., Nishi, N., Shoji, H., Seki, M., Hashidate, T., Hirabayashi, J., et al. (2002). Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 12 (3), 191–197. doi:10.1093/glycob/12.3.191
Sher, A., and Coffman, R. L. (1992). Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10, 385–409. doi:10.1146/annurev.iy.10.040192.002125
Street, N. E., and Mosmann, T. R. (1991). Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 5 (2), 171–177. doi:10.1096/fasebj.5.2.1825981
Su, S., Zhao, J., Xing, Y., Zhang, X., Liu, J., Ouyang, Q., et al. (2018). Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell 175 (2), 442–457. doi:10.1016/j.cell.2018.09.007
Sun, X., Wang, W. J., Lang, J., Yang, R., Shen, W. J., Sun, L., et al. (2023). Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. Int. J. Biol. Sci. 19 (14), 4644–4656. doi:10.7150/ijbs.84108
Suszczyk, D., Skiba, W., Pawłowska, A., Polak, G., Tarkowski, R., and Wertel, I. (2023). Expression of gal-9 on dendritic cells and soluble forms of TIM-3/gal-9 in patients suffering from endometriosis. Int. J. Mol. Sci. 24 (6), 5948. doi:10.3390/ijms24065948
Tadokoro, T., Morishita, A., Fujihara, S., Iwama, H., Niki, T., Fujita, K., et al. (2016). Galectin-9: an anticancer molecule for gallbladder carcinoma. Int. J. Oncol. 48 (3), 1165–1174. doi:10.3892/ijo.2016.3347
Taghiloo, S., Allahmoradi, E., Ebadi, R., Tehrani, M., Hosseini-Khah, Z., Janbabaei, G., et al. (2017). Upregulation of galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic lymphocytic leukemia. Asian Pac J. Cancer Prev. 18 (8), 2269–2274. doi:10.22034/APJCP.2017.18.8.2269
Takano, J., Morishita, A., Fujihara, S., Iwama, H., Kokado, F., Fujikawa, K., et al. (2016). Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncol. Rep. 35 (2), 851–860. doi:10.3892/or.2015.4452
Tang, X. Y., Luo, Z. L., Xiong, Y. L., Yang, J., Shi, A. P., Zheng, K. F., et al. (2022). The proliferative role of immune checkpoints in tumors: double regulation. Cancers (Basel) 14 (21), 5374. doi:10.3390/cancers14215374
Thorman, J., Björkman, P., Sasinovich, S., Tesfaye, F., Mulleta, D., Medstrand, P., et al. (2023). Performance of galectin-9 for identification of HIV viremia in adults receiving antiretroviral therapy in a resource-limited setting. J. Acquir Immune Defic. Syndr. 93 (3), 244–250. doi:10.1097/QAI.0000000000003196
Tontonoz, P., and Spiegelman, B. M. (2008). Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289–312. doi:10.1146/annurev.biochem.77.061307.091829
Wada, J., and Kanwar, Y. S. (1997). Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J. Biol. Chem. 272 (9), 6078–6086. doi:10.1074/jbc.272.9.6078
Wang, M., Cai, Y., Peng, Y., Xu, B., Hui, W., and Jiang, Y. (2020b). Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity. Cell Death Dis. 11 (10), 896. doi:10.1038/s41419-020-03042-3
Wang, R., Song, S., Harada, K., Ghazanfari Amlashi, F., Badgwell, B., Pizzi, M. P., et al. (2020a). Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69 (1), 18–31. doi:10.1136/gutjnl-2018-318070
Wang, Y., Zhao, E., Zhang, Z., Zhao, G., and Cao, H. (2018). Association between Tim-3 and Gal-9 expression and gastric cancer prognosis. Oncol. Rep. 40 (4), 2115–2126. doi:10.3892/or.2018.6627
Wiersma, V. R., de Bruyn, M., Helfrich, W., and Bremer, E. (2013). Therapeutic potential of Galectin-9 in human disease. Med. Res. Rev. 33 (Suppl. 1), E102–E126. doi:10.1002/med.20249
Wiersma, V. R., de Bruyn, M., van Ginkel, R. J., Sigar, E., Hirashima, M., Niki, T., et al. (2012). The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J. Invest. Dermatol 132 (9), 2302–2305. doi:10.1038/jid.2012.133
Wiersma, V. R., de Bruyn, M., Wei, Y., van Ginkel, R. J., Hirashima, M., Niki, T., et al. (2015). The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy 11 (8), 1373–1388. doi:10.1080/15548627.2015.1063767
Yamauchi, A., Kontani, K., Kihara, M., Nishi, N., Yokomise, H., and Hirashima, M. (2006). Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J. 12 (5 Suppl. 2), S196–S200. doi:10.1111/j.1075-122X.2006.00334.x
Yang, J., Zhu, L., Cai, Y., Suo, J., and Jin, J. (2014). Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. Int. J. Oncol. 45 (3), 1313–1320. doi:10.3892/ijo.2014.2494
Yang, R., Sun, L., Li, C. F., Wang, Y. H., Yao, J., Li, H., et al. (2021). Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12 (1), 832. doi:10.1038/s41467-021-21099-2
Yasinska, I. M., Meyer, N. H., Schlichtner, S., Hussain, R., Siligardi, G., Casely-Hayford, M., et al. (2020). Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity. Front. Immunol. 11, 580557. doi:10.3389/fimmu.2020.580557
Yasinska, I. M., Sakhnevych, S. S., Pavlova, L., Teo Hansen Selnø, A., Teuscher Abeleira, A. M., Benlaouer, O., et al. (2019). The tim-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front. Immunol. 10, 1594. doi:10.3389/fimmu.2019.01594
Yoon, H. K., Kim, T. H., Park, S., Jung, H., Quan, X., Park, S. J., et al. (2018). Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer. Pathol. Res. Pract. 214 (10), 1626–1631. doi:10.1016/j.prp.2018.08.009
Yoshikawa, K., Ishida, M., Yanai, H., Tsuta, K., Sekimoto, M., and Sugie, T. (2022). Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer. Oncol. Lett. 23 (6), 197. doi:10.3892/ol.2022.13318
Yu, Y., Liu, J., Liu, C., Liu, R., Liu, L., Yu, Z., et al. (2022). Post-translational modifications of cGAS-STING: a critical switch for immune regulation. Cells 11 (19), 3043. doi:10.3390/cells11193043
Yuan, F., Ming, H., Wang, Y., Yang, Y., Yi, L., Li, T., et al. (2020). Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples. J. Cell Physiol. 235 (5), 4326–4334. doi:10.1002/jcp.29309
Zaheed, M., Wilcken, N., Willson, M. L., O'Connell, D. L., and Goodwin, A. (2019). Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst. Rev. 2 (2), CD012873. doi:10.1002/14651858.CD012873.pub2
Zhang, Z. Y., Dong, J. H., Chen, Y. W., Wang, X. Q., Li, C. H., Wang, J., et al. (2012). Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J. Cancer Prev. 13 (6), 2503–2509. doi:10.7314/apjcp.2012.13.6.2503
Zheng, S., Song, J., Linghu, D., Yang, R., Liu, B., Xue, Z., et al. (2023). Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity. Int. J. Biol. Sci. 19 (3), 981–993. doi:10.7150/ijbs.79852
Zheng, Y., Feng, W., Wang, Y. J., Sun, Y., Shi, G., and Yu, Q. (2019). Galectins as potential emerging key targets in different types of leukemia. Eur. J. Pharmacol. 844, 73–78. doi:10.1016/j.ejphar.2018.11.019
Zhou, X., Sun, L., Jing, D., Xu, G., Zhang, J., Lin, L., et al. (2018). Galectin-9 expression predicts favorable clinical outcome in solid tumors: a systematic review and meta-analysis. Front. Physiol. 9, 452. doi:10.3389/fphys.2018.00452
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., et al. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6 (12), 1245–1252. doi:10.1038/ni1271
Glossary
Keywords: galectin-9, pan-cancer, biological functions, therapeutic target, immunotharapy
Citation: Zhang M, Liu C, Li Y, Li H, Zhang W, Liu J, Wang L and Sun C (2024) Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target. Front. Cell Dev. Biol. 11:1332205. doi: 10.3389/fcell.2023.1332205
Received: 02 November 2023; Accepted: 22 December 2023;
Published: 09 January 2024.
Edited by:
Qinong Ye, Beijing Institute of Biotechnology, ChinaReviewed by:
Yu-gang Huang, Hubei University of Medicine, ChinaWei Huang, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Copyright © 2024 Zhang, Liu, Li, Li, Zhang, Liu, Wang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Changgang Sun, scgdoctor@126.com